Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Clinical trial NCT04700124 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04700124
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-21
- Primary completion
- 2025-10-27
- Enrollment
- 808
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.